Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

How Did Telma Become a 1000+ Cr Brand?

The untold story of Glenmark's phenomenal success in building...

Sales View – On-the-Go Information, Insights & Learning for Pharma Professionals

Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance (IPA)...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Marketing

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Policies/Sales

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Strategy

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Astra Zeneca Tops Indian Pharma in New Introductions 2024

Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...

Pharma – Physician Interactions in the Digital Era

Indian Pharma companies will have to create hybrid employees, who can be designated as the Digital Task Force (DTF). Just as STFs were created to create a better perception and improve engagement with specialist doctors, DTF can rebuild relationships with doctors on a new premise of helping them to gain digital advantage to better manage their practice and patients.

Is Indian Pharma Singing Digital Without Lyrics?

A large part of the pharma houses continues to...

Pharma in the New Normal

2020 has been a challenging year for all industries. For pharma and its HCP customers even more so. All eyes are on the companies developing vaccines and drugs for treatment of COVID-19, while doctors have closed their doors for pharma reps. Long established processes have been disrupted and complex market strategies have been rendered useless. Each pharma no matter big or small, innovative, or generic, had to improvise and come up with contingency plans to save the year. Some have been slower waiting for the old ways to come back, others have been more agile experimenting with digital and expanding boundaries, most are in the middle digitally curious but not risking too much.